Educational only — this site does not provide personalised medical advice. Read the full disclaimer.
The Longevity Review Without the sales pitch
Moderate

EBV Testing for Nasopharyngeal Cancer

Last reviewed 25 August 2026 · Evidence-graded review — see Methodology

A test whose value depends almost entirely on where you live and whose ancestry you have. Nasopharyngeal carcinoma is rare in most of the world and markedly more common in southern Chinese and Southeast Asian populations, which makes this region one of the few places where screening for it has a serious case. The complication is that most packages include the antibody version, and the evidence is for a different test.

Why it grades Moderate

Chan KCA, Woo JKS, et al. “Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.” N Engl J Med 2017;377:513–522 screened 20,174 middle-aged men in Hong Kong using plasma EBV DNA and detected nasopharyngeal carcinoma at a substantially earlier stage, with better progression-free survival, than in unscreened historical controls. Two things keep this at Moderate: the trial used cell-free EBV DNA rather than the IgA serology bundled into most Singapore packages, and it has not been compared against no screening for mortality in a randomised design.

Chan KCA, et al. N Engl J Med. 2017. PubMed: PMID 28792880

FrequencyNot established; the trial screened once, repeating within four weeks for positives
Cost (SGD)S$40–90 (IgA serology); plasma EBV DNA testing is less widely offered and costs more
Appropriate forAdults of southern Chinese or Southeast Asian ancestry, particularly men over 40 or with a family history of nasopharyngeal cancer

Singapore guidance

Not covered in the current review

Singapore’s national screening committee has not reviewed this test in the current volume of its report, which covers nine conditions. That is not a verdict either way.

Source: Screening Test Review Committee report 2026, Volume 1 (Academy of Medicine Singapore and Ministry of Health, February 2026). The full national list · How this is used.

What you would actually pay

Healthier SG
Not subsidised
MediSave
Not among the screenings named for outpatient claims

Source: Healthier SG Screening (HealthHub) and MediSave outpatient care (Ministry of Health). Absence from either list is not a statement that the test is discouraged — only that no subsidy or claim applies. Gross prices compared.

What it costs when it is wrong

Basis
No published harm criterion found
Severity
Not documented

Not covered in the current volume of the committee’s report, so no harm criterion was found either way.

An empty finding, not a clean bill of health: this means nothing documented was found for this test. It is not a claim that the test is safe.

Screening harm is not only a laboratory question: the committee’s own criteria advise against a test when “the screening test, or follow-up tests arising from a positive screen, are associated with significant medical risks”. Sources on overdiagnosis → · How this is graded.

FAQ

Is the EBV Testing for Nasopharyngeal Cancer worth doing in Singapore?

For adults without symptoms, EBV Testing for Nasopharyngeal Cancer sits at the moderate grade on our evidence scale. Most appropriate for adults of southern Chinese or Southeast Asian ancestry, particularly men over 40 or with a family history of nasopharyngeal cancer. It typically costs S$40–90 in Singapore. It is not established; the trial screened once, repeating within four weeks for positives.

Weighing this against something else? Compare it with two other tests → · Price it inside a panel →